Search

Your search keyword '"Chapuis N"' showing total 209 results
Start Over Author "Chapuis N"
209 results on '"Chapuis N"'

2. Topic: AS01-Diagnosis/AS01b-Flow cytometry: COMMITTED AND IMMATURE ERYTHROID PROGENITORS ARE DIFFERENTLY DISTRIBUTED IN LOWER RISK MYELODYSPLASTIC SYNDROMES ACCORDING TO WHO CATEGORY AND CORRELATE WITH RESPONSE TO ERYTHROPOIESIS STIMULATING AGENTS

Author

Raddi, M.G., primary, Consagra, A., additional, Rigodanza, L., additional, Amato, C., additional, Tofacchi, E., additional, Cassari, M., additional, De Pourcq, S., additional, Mattiuz, G., additional, Bencini, S., additional, Peruzzi, B., additional, Sanna, A., additional, Annunziato, F., additional, Fontenay, M., additional, Chapuis, N., additional, and Santini, V., additional

Published
2023
Full Text
View/download PDF

3. Topic: AS04-MDS Biology and Pathogenesis/AS04e-Spliceosome machinery: DNA REPLICATION STRESS DUE TO LOSS OF R-LOOPS IN MYELODYSPLASTIC SYNDROMES WITH SF3B1 MUTATION

Author

Rombaut, D., primary, Lefevre, C., additional, Farhat, B., additional, Bondu, S., additional, Letessier, A., additional, Lesieur-Pasquier, A., additional, Castillo-Guzman, D., additional, Leduc, M., additional, Hartono, S., additional, Chesnais, V., additional, Mangione, R., additional, Boussaid, I., additional, Houy, A., additional, Bouscary, D., additional, Willems, L., additional, Chapuis, N., additional, Kosmider, O., additional, Park, S., additional, Raynaud, S., additional, Cluzeau, T., additional, Clappier, E., additional, Fenaux, P., additional, Ades, L., additional, Margueron, R., additional, Wassef, M., additional, Alsafadi, S., additional, Solary, E., additional, Constantinou, A., additional, Stern, M.-H., additional, Palancade, B., additional, Droin, N., additional, Miotto, B., additional, Chédin, F., additional, and Fontenay, M., additional

Published
2023
Full Text
View/download PDF

4. Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet

Author

van der Velden, VHJ, Preijers, F, Johansson, U, Westers, TM, Dunlop, A, Porwit, A, Bene, MC, Valent, P, te Marvelde, J, Wagner-Ballon, O, Oelschlaegel, U, Saft, L, Kordasti, S, Ireland, R, Cremers, E, Alhan, C, Duetz, C, Hobo, W, Chapuis, N, Fontenay, M, Bettelheim, P, Eidenshink-Brodersen, L, Font, P, Loken, MR, Matarraz, S, Ogata, K, Orfao, A, Psarra, K, Subira, D, Wells, DA, Della Porta, MG, Burbury, K, Bellos, F, Weiss, E, Kern, W, van de Loosdrecht, A, van der Velden, VHJ, Preijers, F, Johansson, U, Westers, TM, Dunlop, A, Porwit, A, Bene, MC, Valent, P, te Marvelde, J, Wagner-Ballon, O, Oelschlaegel, U, Saft, L, Kordasti, S, Ireland, R, Cremers, E, Alhan, C, Duetz, C, Hobo, W, Chapuis, N, Fontenay, M, Bettelheim, P, Eidenshink-Brodersen, L, Font, P, Loken, MR, Matarraz, S, Ogata, K, Orfao, A, Psarra, K, Subira, D, Wells, DA, Della Porta, MG, Burbury, K, Bellos, F, Weiss, E, Kern, W, and van de Loosdrecht, A

Abstract

BACKGROUND: Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. METHODS: Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. RESULTS: We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. CONCLUSIONS: These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.

Published
2023

5. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

Author

Loosdrecht, AA, Kern, W, Porwit, A, Valent, P, Kordasti, S, Cremers, E, Alhan, C, Duetz, C, Dunlop, A, Hobo, W, Preijers, F, Wagner-Ballon, O, Chapuis, N, Fontenay, M, Bettelheim, P, Eidenschink-Brodersen, L, Font, P, Johansson, U, Loken, MR, Marvelde, JG, Matarraz, S, Ogata, K, Oelschlaegel, U, Orfao, A, Psarra, K, Subira, D, Wells, DA, Bene, MC, Della Porta, MG, Burbury, K, Bellos, F, van der Velden, VHJ, Westers, TM, Saft, L, Ireland, R, Loosdrecht, AA, Kern, W, Porwit, A, Valent, P, Kordasti, S, Cremers, E, Alhan, C, Duetz, C, Dunlop, A, Hobo, W, Preijers, F, Wagner-Ballon, O, Chapuis, N, Fontenay, M, Bettelheim, P, Eidenschink-Brodersen, L, Font, P, Johansson, U, Loken, MR, Marvelde, JG, Matarraz, S, Ogata, K, Oelschlaegel, U, Orfao, A, Psarra, K, Subira, D, Wells, DA, Bene, MC, Della Porta, MG, Burbury, K, Bellos, F, van der Velden, VHJ, Westers, TM, Saft, L, and Ireland, R

Abstract

This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

Published
2023

6. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group.

Author

Loosdrecht, A.A. van de, Kern, W., Porwit, A., Valent, P., Kordasti, S., Cremers, E., Alhan, C., Duetz, C., Dunlop, A., Hobo, W.A., Preijers, F.W., Wagner-Ballon, O., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenschink-Brodersen, L., Font, P., Johansson, U., Loken, M.R., Marvelde, J.G. Te, Matarraz, S., Ogata, K., Oelschlaegel, U., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Béné, M.C., Porta, M.G. Della, Burbury, K., Bellos, F., Velden, V.H. van der, Westers, Theresia M., Saft, L., Ireland, R., Loosdrecht, A.A. van de, Kern, W., Porwit, A., Valent, P., Kordasti, S., Cremers, E., Alhan, C., Duetz, C., Dunlop, A., Hobo, W.A., Preijers, F.W., Wagner-Ballon, O., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenschink-Brodersen, L., Font, P., Johansson, U., Loken, M.R., Marvelde, J.G. Te, Matarraz, S., Ogata, K., Oelschlaegel, U., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Béné, M.C., Porta, M.G. Della, Burbury, K., Bellos, F., Velden, V.H. van der, Westers, Theresia M., Saft, L., and Ireland, R.

Abstract

01 januari 2023, Item does not contain fulltext, This article discusses the rationale for inclusion of flow cytometry (FCM) in the diagnostic investigation and evaluation of cytopenias of uncertain origin and suspected myelodysplastic syndromes (MDS) by the European LeukemiaNet international MDS Flow Working Group (ELN iMDS Flow WG). The WHO 2016 classification recognizes that FCM contributes to the diagnosis of MDS and may be useful for prognostication, prediction, and evaluation of response to therapy and follow-up of MDS patients.

Published
2023

7. Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues-Recommendations from the European LeukemiaNet.

Author

Velden, V.H. van der, Preijers, F.W., Johansson, U., Westers, Theresia M., Dunlop, A., Porwit, A., Béné, M.C., Valent, P., Marvelde, J. Te, Wagner-Ballon, O., Oelschlaegel, U., Saft, L., Kordasti, S., Ireland, R., Cremers, E., Alhan, C., Duetz, C., Hobo, W.A., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenshink-Brodersen, L., Font, P., Loken, M.R., Matarraz, S., Ogata, K., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Porta, M.G. Della, Burbury, K., Bellos, F., Weiß, E., Kern, W., Loosdrecht, A. van de, Velden, V.H. van der, Preijers, F.W., Johansson, U., Westers, Theresia M., Dunlop, A., Porwit, A., Béné, M.C., Valent, P., Marvelde, J. Te, Wagner-Ballon, O., Oelschlaegel, U., Saft, L., Kordasti, S., Ireland, R., Cremers, E., Alhan, C., Duetz, C., Hobo, W.A., Chapuis, N., Fontenay, M., Bettelheim, P., Eidenshink-Brodersen, L., Font, P., Loken, M.R., Matarraz, S., Ogata, K., Orfao, A., Psarra, K., Subirá, D., Wells, D.A., Porta, M.G. Della, Burbury, K., Bellos, F., Weiß, E., Kern, W., and Loosdrecht, A. van de

Abstract

01 januari 2023, Item does not contain fulltext, BACKGROUND: Flow cytometry (FCM) aids the diagnosis and prognostic stratification of patients with suspected or confirmed myelodysplastic syndrome (MDS). Over the past few years, significant progress has been made in the FCM field concerning technical issues (including software and hardware) and pre-analytical procedures. METHODS: Recommendations are made based on the data and expert discussions generated from 13 yearly meetings of the European LeukemiaNet international MDS Flow working group. RESULTS: We report here on the experiences and recommendations concerning (1) the optimal methods of sample processing and handling, (2) antibody panels and fluorochromes, and (3) current hardware technologies. CONCLUSIONS: These recommendations will support and facilitate the appropriate application of FCM assays in the diagnostic workup of MDS patients. Further standardization and harmonization will be required to integrate FCM in MDS diagnostic evaluations in daily practice.

Published
2023

8. Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group.

Author

Porwit, A., Béné, M.C., Duetz, C., Matarraz, S., Oelschlaegel, U., Westers, Theresia M., Wagner-Ballon, O., Kordasti, S., Valent, P., Preijers, F.W., Alhan, C., Bellos, F., Bettelheim, P., Burbury, K., Chapuis, N., Cremers, E., Porta, M.G. Della, Dunlop, A., Eidenschink-Brodersen, L., Font, P., Fontenay, M., Hobo, W., Ireland, R., Johansson, U., Loken, M.R., Ogata, K., Orfao, A., Psarra, K., Saft, L., Subira, D., Marvelde, J. Te, Wells, D.A., Velden, V.H. van der, Kern, W., Loosdrecht, A.A. van de, Porwit, A., Béné, M.C., Duetz, C., Matarraz, S., Oelschlaegel, U., Westers, Theresia M., Wagner-Ballon, O., Kordasti, S., Valent, P., Preijers, F.W., Alhan, C., Bellos, F., Bettelheim, P., Burbury, K., Chapuis, N., Cremers, E., Porta, M.G. Della, Dunlop, A., Eidenschink-Brodersen, L., Font, P., Fontenay, M., Hobo, W., Ireland, R., Johansson, U., Loken, M.R., Ogata, K., Orfao, A., Psarra, K., Saft, L., Subira, D., Marvelde, J. Te, Wells, D.A., Velden, V.H. van der, Kern, W., and Loosdrecht, A.A. van de

Abstract

01 januari 2023, Item does not contain fulltext, Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (MDS). MFC can also be applied in the follow-up of MDS patients undergoing treatment. This document summarizes recommendations from the International/European Leukemia Net Working Group for Flow Cytometry in Myelodysplastic Syndromes (ELN iMDS Flow) on the analytical issues in MFC for the diagnostic work-up of MDS. Recommendations for the analysis of several BM cell subsets such as myeloid precursors, maturing granulocytic and monocytic components and erythropoiesis are given. A core set of 17 markers identified as independently related to a cytomorphologic diagnosis of myelodysplasia is suggested as mandatory for MFC evaluation of BM in a patient with cytopenia. A myeloid precursor cell (CD34(+) CD19(-) ) count >3% should be considered immunophenotypically indicative of myelodysplasia. However, MFC results should always be evaluated as part of an integrated hematopathology work-up. Looking forward, several machine-learning-based analytical tools of interest should be applied in parallel to conventional analytical methods to investigate their usefulness in integrated diagnostics, risk stratification, and potentially even in the evaluation of response to therapy, based on MFC data. In addition, compiling large uniform datasets is desirable, as most of the machine-learning-based methods tend to perform better with larger numbers of investigated samples, especially in such a heterogeneous disease as MDS.

Published
2023

9. Molecular beam epitaxy of TaSe2 on GaP(111)B

Author

Sthioul, C., Koussir, H., Chernukha, Y., Chapuis, N., Haber, E., Coinon, Christophe, Diener, Pascale, Grandidier, B., Wallart, Xavier, Institut d’Électronique, de Microélectronique et de Nanotechnologie - UMR 8520 (IEMN), Centrale Lille-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université Polytechnique Hauts-de-France (UPHF)-JUNIA (JUNIA), Université catholique de Lille (UCL)-Université catholique de Lille (UCL), EPItaxie et PHYsique des hétérostructures - IEMN (EPIPHY - IEMN), Université catholique de Lille (UCL)-Université catholique de Lille (UCL)-Centrale Lille-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université Polytechnique Hauts-de-France (UPHF)-JUNIA (JUNIA), Centrale de Micro Nano Fabrication - IEMN (CMNF - IEMN), Physique - IEMN (PHYSIQUE - IEMN), NANODYN - ANR-21-CE24-0001 AAPG2021 - 2021TUNNE2D - ANR-21-CE24-0030 AAPG2021 - 2021, Renatech Network, PCMP PCP, CMNF, ANR-21-CE24-0030,TUNNE2D,Diodes tunnel miniaturisables à base de matériaux 2D(2021), and ANR-21-CE24-0001,NANODYN,Transition de Mott hors équilibre pour la Nanoélectronique(2021)

Subjects
[PHYS]Physics [physics], TaSe2, GaP(111)B, [SPI]Engineering Sciences [physics], Molecular beam epitaxy
Abstract

National audience

Published
2023

10. Key parameters for GaP(111)B surface preparation and Selenium passivation

Author

Chapuis, N., Sthioul, C., Coinon, Christophe, Desplanque, L., Wallart, X., Institut d’Électronique, de Microélectronique et de Nanotechnologie - UMR 8520 (IEMN), Centrale Lille-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université Polytechnique Hauts-de-France (UPHF)-JUNIA (JUNIA), Université catholique de Lille (UCL)-Université catholique de Lille (UCL), EPItaxie et PHYsique des hétérostructures - IEMN (EPIPHY - IEMN), Université catholique de Lille (UCL)-Université catholique de Lille (UCL)-Centrale Lille-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université Polytechnique Hauts-de-France (UPHF)-JUNIA (JUNIA), Centrale de Micro Nano Fabrication - IEMN (CMNF - IEMN), TUNNE2D - ANR-21-CE24-0030 AAPG2021 - 2021, Renatech Network, CMNF, and ANR-21-CE24-0030,TUNNE2D,Diodes tunnel miniaturisables à base de matériaux 2D(2021)

Subjects
[PHYS]Physics [physics], [SPI]Engineering Sciences [physics]
Abstract

International audience

Published
2023

11. High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells

Author

Poulain, L, Sujobert, P, Zylbersztejn, F, Barreau, S, Stuani, L, Lambert, M, Palama, T L, Chesnais, V, Birsen, R, Vergez, F, Farge, T, Chenevier-Gobeaux, C, Fraisse, M, Bouillaud, F, Debeissat, C, Herault, O, Récher, C, Lacombe, C, Fontenay, M, Mayeux, P, Maciel, T T, Portais, J-C, Sarry, J-E, Tamburini, J, Bouscary, D, and Chapuis, N

Published
2017
Full Text
View/download PDF

12. P057 - Topic: AS04-MDS Biology and Pathogenesis/AS04e-Spliceosome machinery: DNA REPLICATION STRESS DUE TO LOSS OF R-LOOPS IN MYELODYSPLASTIC SYNDROMES WITH SF3B1 MUTATION

Author

Rombaut, D., Lefevre, C., Farhat, B., Bondu, S., Letessier, A., Lesieur-Pasquier, A., Castillo-Guzman, D., Leduc, M., Hartono, S., Chesnais, V., Mangione, R., Boussaid, I., Houy, A., Bouscary, D., Willems, L., Chapuis, N., Kosmider, O., Park, S., Raynaud, S., Cluzeau, T., Clappier, E., Fenaux, P., Ades, L., Margueron, R., Wassef, M., Alsafadi, S., Solary, E., Constantinou, A., Stern, M.-H., Palancade, B., Droin, N., Miotto, B., Chédin, F., and Fontenay, M.

Published
2023
Full Text
View/download PDF

13. P006 - Topic: AS01-Diagnosis/AS01b-Flow cytometry: COMMITTED AND IMMATURE ERYTHROID PROGENITORS ARE DIFFERENTLY DISTRIBUTED IN LOWER RISK MYELODYSPLASTIC SYNDROMES ACCORDING TO WHO CATEGORY AND CORRELATE WITH RESPONSE TO ERYTHROPOIESIS STIMULATING AGENTS

Author

Raddi, M.G., Consagra, A., Rigodanza, L., Amato, C., Tofacchi, E., Cassari, M., De Pourcq, S., Mattiuz, G., Bencini, S., Peruzzi, B., Sanna, A., Annunziato, F., Fontenay, M., Chapuis, N., and Santini, V.

Published
2023
Full Text
View/download PDF

22. PREDICTIVE VALUE OF FDG PET/CT IN PATIENTS WITH RELAPSE/REFRACTORY MULTIPLE MYELOMA BEFORE TREATMENT WITH ANTI‐CD38 IMMUNOTHERAPY

Author

Fouquet, G., primary, Wartski, M., additional, Dechmi, A., additional, Willems, L., additional, Deau‐Fischer, B., additional, Franchi, P., additional, Descroocq, J., additional, Deschamps, P., additional, Clerc, J., additional, Bouscary, D., additional, Barreau, S., additional, Chapuis, N., additional, Vignon, M., additional, and Cottereau, A.‐S., additional

Published
2021
Full Text
View/download PDF

27. Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma

Author

Kramkimel, N., primary, Thomas-Schoemann, A., additional, Sakji, L., additional, Golmard, JL., additional, Noe, G., additional, Regnier-Rosencher, E., additional, Chapuis, N., additional, Maubec, E., additional, Vidal, M., additional, Avril, MF., additional, Goldwasser, F., additional, Mortier, L., additional, Dupin, N., additional, and Blanchet, B., additional

Published
2015
Full Text
View/download PDF

28. Targeted inhibition of mtor by azd8055 blocks protein translation and has anti-leukemic activity in acute myeloid leukemia

Author

Willems, L, Chapuis, N., Green, A., Bardet, V., Jacque, N., Park, S., Ifrah, N., Dreyfus, F, Guichard, S, Mayeux, P, Lacombe, Claire, Bouscary, D., Tamburini, J., Université Pierre et Marie Curie - Paris 6 (UPMC), Protéines : biochimie structurale et fonctionnelle (PBSF), Université Pierre et Marie Curie - Paris 6 (UPMC)-Centre National de la Recherche Scientifique (CNRS), and Perron, Nicolas

Subjects
[CHIM.ORGA]Chemical Sciences/Organic chemistry, [CHIM.ORGA] Chemical Sciences/Organic chemistry, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2010

29. 104 APG101 (SOLUBLE CD95-FC) IMPROVES BFU-E GROWTH IN LOWER RISK MYELODYSPLASTIC SYNDROME WITH COLLAPSED ERYTHROPOIESIS: A PRECLINICAL STUDY

Author

Raimbault, A., primary, Bondu, S., additional, Pierre-Eugene, C., additional, Deudon, C., additional, Willems, L., additional, Frisan, E., additional, Chapuis, N., additional, Sapena, R., additional, Rouquette, A., additional, Kunz, C., additional, Fricke, H., additional, Kosmider, O., additional, Bardet, V., additional, and Fontenay, M., additional

Published
2015
Full Text
View/download PDF

30. Pain reactivity and plasma beta-endorphin in children and adolescents with autistic disorder

Author

Poulain, L., Sujobert, P., Zylbersztejn, F., Barreau, S., Lambert, M., Chesnais, V., Birsen, R, Vergez, F., Farge, T., Chenevier-Gobeaux, C., Fraisse, M., Bouillaud, F., Debeissat, C., Herault, O., Récher, C., Lacombe, C., Fontenay, M., Mayeux, P., Maciel, T. T., Sarry, J.E., Tamburini, J., Bouscary, D., Chapuis, N., Laboratoire psychologie de la perception (LPP), Département d'Etudes Cognitives - ENS Paris (DEC), École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Descartes - Paris 5 (UPD5)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES), Yale University [New Haven], Récepteurs stéroïdiens : physiopathologie endocrinienne et métabolique, Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR93-Université Paris-Sud - Paris 11 (UP11), AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Centre Emotion, Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de psychologie cognitive (LPC), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Génétique Médicale et Génomique Fonctionnelle (GMGF), Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Centre National de la Recherche Scientifique (CNRS), Aix-Marseille Université - Faculté de médecine (AMU MED), Aix Marseille Université (AMU), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Ligue Nationale Contre le Cancer - Paris, Ligue Nationale Contre le Cancer (LNCC), Université Sorbonne Paris Cité (USPC), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d'Ingénierie des Systèmes Biologiques et des Procédés (LISBP), Institut National de la Recherche Agronomique (INRA)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS), UMR1037, Cancer Research Center of Toulouse, Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpitaux Universitaires Paris Centre, Service de Diagnostic Biologique Automatisé, Assistance Publique - Hôpitaux de Paris, Génétique, immunothérapie, chimie et cancer (GICC), UMR 6239 CNRS [2008-2011] (GICC UMR 6239 CNRS), Université de Tours (UT)-Centre National de la Recherche Scientifique (CNRS), Institut Cochin (UMR_S567 / UMR 8104), Equipe Labellisée, Hôpitaux Universitaires Paris Centre, Service d'Hématologie biologique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS-PSL), Université de Rennes (UR), Université Paris-Sud - Paris 11 (UP11)-IFR93-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Ligue Nationnale Contre le Cancer, Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Ligue Nationale Contre le Cancer, Pérez-Diaz, Fernando, Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Recherche Agronomique (INRA), Université de Tours-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), and Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, medicine.medical_specialty, Adolescent, Pain, lcsh:Medicine, Biology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, [SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics, Internal medicine, Heart rate, mental disorders, medicine, Humans, [SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Autistic Disorder, Reactivity (psychology), Psychiatry, Child, lcsh:Science, 030304 developmental biology, 0303 health sciences, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, Multidisciplinary, Venipuncture, beta-Endorphin, lcsh:R, Case-control study, Genetics and Genomics/Gene Expression, medicine.disease, Mental Health/Child and Adolescent Psychiatry, Mental Health, Opioid, chemistry, Case-Control Studies, Autism, Female, lcsh:Q, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], 030217 neurology & neurosurgery, medicine.drug, Blood drawing, Research Article
Abstract

International audience; Background: Reports of reduced pain sensitivity in autism have prompted opioid theories of autism and have practical care ramifications. Our objective was to examine behavioral and physiological pain responses, plasma β-endorphin levels and their relationship in a large group of individuals with autism.Methodology/Principal Findings: The study was conducted on 73 children and adolescents with autism and 115 normal individuals matched for age, sex and pubertal stage. Behavioral pain reactivity of individuals with autism was assessed in three observational situations (parents at home, two caregivers at day-care, a nurse and child psychiatrist during blood drawing), and compared to controls during venepuncture. Plasma β-endorphin concentrations were measured by radioimmunoassay. A high proportion of individuals with autism displayed absent or reduced behavioral pain reactivity at home (68.6%), at day-care (34.2%) and during venepuncture (55.6%). Despite their high rate of absent behavioral pain reactivity during venepuncture (41.3 vs. 8.7% of controls, P

Published
2009
Full Text
View/download PDF

33. The esterase-like activity of serum albumin may be due to cholinesterase contamination

Author

Chapuis, N., Bruhlmann, C., Reist, Marianne, Carrupt, Pierre-Alain, Mayer, J. M., and Testa, Bernard

Subjects
ddc:615, Butyrylcholinesterase/metabolism, Hydrolysis, Physostigmine, Esterases, Ultrafiltration, Fatty Acids, Nonesterified, Esterases/*chemistry/*metabolism, Cholinesterase Inhibitors/pharmacology, Chromatography, Affinity, body regions, Moxisylyte, Physostigmine/pharmacology, Serum Albumin/*chemistry/*metabolism, Butyrylcholinesterase, embryonic structures, Cholinesterases, Humans, Fatty Acids, Nonesterified/metabolism, Moxisylyte/chemistry, Fluorometry, Cholinesterase Inhibitors, Drug Contamination, Serum Albumin, Cholinesterases/*chemistry/*metabolism
Abstract

PURPOSE: The "esterase-like activity" of human serum albumin (HSA) is described in the literature, but a contamination of commercially available HSA preparations by plasma cholinesterase is conceivable in some cases. The purpose of the present work was to examine this hypothesis. METHODS: The hydrolytic activity of HSA and its inhibition by physostigmine were measured fluorimetrically by monitoring the hydrolysis of the ester substrate moxisylyte. Affinity chromatography was used to separate cholinesterase and HSA. The cholinesterase activity in the eluted fractions was assessed using Ellman's reagent and butyrylthiocholine as substrate. RESULTS: A significant variation in the esterase-like activity of different albumin batches was observed. This activity was strongly inhibited by physostigmine, a well-known inhibitor of cholinesterase. Affinity chromatography led to a complete separation between HSA and the esterase activity, which was found exclusively in the cholinesterase fraction. CONCLUSIONS: The apparent esterase-like activity of HSA toward moxisylyte and butyrylthiocholine was due to a contamination by cholinesterase. With these substrates, HSA showed a total lack of esterase-like activity.

Published
2001

35. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia

Author

Willems, L, primary, Chapuis, N, additional, Puissant, A, additional, Maciel, T T, additional, Green, A S, additional, Jacque, N, additional, Vignon, C, additional, Park, S, additional, Guichard, S, additional, Herault, O, additional, Fricot, A, additional, Hermine, O, additional, Moura, I C, additional, Auberger, P, additional, Ifrah, N, additional, Dreyfus, F, additional, Bonnet, D, additional, Lacombe, C, additional, Mayeux, P, additional, Bouscary, D, additional, and Tamburini, J, additional

Published
2011
Full Text
View/download PDF

36. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study

Author

Vergez, F., primary, Green, A. S., additional, Tamburini, J., additional, Sarry, J.-E., additional, Gaillard, B., additional, Cornillet-Lefebvre, P., additional, Pannetier, M., additional, Neyret, A., additional, Chapuis, N., additional, Ifrah, N., additional, Dreyfus, F., additional, Manenti, S., additional, Demur, C., additional, Delabesse, E., additional, Lacombe, C., additional, Mayeux, P., additional, Bouscary, D., additional, Recher, C., additional, and Bardet, V., additional

Published
2011
Full Text
View/download PDF

38. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody

Author

Chapuis, N., primary, Tamburini, J., additional, Cornillet-Lefebvre, P., additional, Gillot, L., additional, Bardet, V., additional, Willems, L., additional, Park, S., additional, Green, A. S, additional, Ifrah, N., additional, Dreyfus, F., additional, Mayeux, P., additional, Lacombe, C., additional, and Bouscary, D., additional

Published
2009
Full Text
View/download PDF

42. Dissociation of Mechanisms Involved in Dogs’ Oriented Displacements

Author

Chapuis, N., Thinus-Blanc, C., and Poucet, B.

Abstract

Factors determining spatial choice were studied in experiments conducted outdoors. Six dogs (Breton spaniel) had to choose between two paths leading to a baited feeding bowl (goal). Transparent or opaque screens were interposed between the starting-point and the goal; their arrangement was devised so as to control the length and the angular deviation or divergence of the paths. The results show that when the goal was visible (transparent screens) dogs preferred the less divergent path indicating that angular deviation was the most relevant variable. When the goal was hidden (opaque screen), they preferred the shorter path and did not take into account the angular deviation. These results suggest that two classes of mechanism underlie the selection of path in these spatial situations.

Published
1983
Full Text
View/download PDF

50. Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.

Author

Garciaz S, Dumas PY, Bertoli S, Sallman DA, Decroocq J, Belhabri A, Orvain C, Aspas Requena G, Simand C, Laribi K, Carré M, Santagostino A, Himberlin C, Peterlin P, Bonnet S, Chan O, Lancet J, Komrokji R, Vergez F, Chapuis N, Raskovalova T, Plesa A, Lhoumeau AC, Mineur A, Hospital MA, Pigneux A, Vey N, and Récher C

Subjects
Humans, Male, Female, Middle Aged, Aged, Retrospective Studies, Treatment Outcome, Adult, Mutation, Aged, 80 and over, Disease-Free Survival, Isocitrate Dehydrogenase genetics, Withholding Treatment statistics & numerical data, Bridged Bicyclo Compounds, Heterocyclic therapeutic use, Bridged Bicyclo Compounds, Heterocyclic administration & dosage, Azacitidine therapeutic use, Azacitidine administration & dosage, Sulfonamides administration & dosage, Sulfonamides therapeutic use, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute mortality, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols administration & dosage
Abstract

Venetoclax-azacitidine is the standard of treatment for unfit acute myeloid leukemia patients. In the VIALE-A study, treatment was given until progression but there are no data on its optimal duration for responding patients who do not tolerate indefinite therapy. We retrospectively analyzed the outcome of patients who discontinued venetoclax or venetoclax-azacitidine due to poor tolerance. Sixty-two newly diagnosed (ND) AML patients and 22 patients with morphological relapse or refractory AML were included. In the ND cohort (n = 62), 28 patients stopped venetoclax and azacitidine and 34 patients continued azacitidine monotherapy. With a median follow-up of 23 months (IQR, 20-32), median overall survival and treatment-free survival were 44 (IQR, 16-NR) and 16 (IQR, 8-27) months, respectively. Patients who stopped both treatments and those who continued azacitidine monotherapy had the same outcomes. Negative minimal residual disease was associated with a 2-year treatment-free survival of 80%. In the RR cohort (n = 22), median overall survival and treatment-free survival were 19 (IQR, 17-31) and 10 (IQR, 5-NR) months, respectively. Prior number of venetoclax-azacitidine cycles and IDH mutations were associated with increased overall survival. The only factor significantly impacting treatment-free survival was the number of prior cycles. This study suggests that patients who discontinued treatment in remission have favorable outcomes supporting the rationale for prospective controlled trials., (© 2024 The Author(s). American Journal of Hematology published by Wiley Periodicals LLC.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results